Showing 5,801 - 5,820 results of 60,129 for search '(( 50 ((nn decrease) OR (a decrease)) ) OR ( 5 ((we decrease) OR (teer decrease)) ))', query time: 0.75s Refine Results
  1. 5801

    LPC-DHA affects membrane phospholipid saturation. by Jia Pei Chan (5593388)

    Published 2018
    “…<p>Targeted lipidomic analysis of NSC<sup>WT</sup> and NSC<sup>KO</sup> cells treated with or without 50 μM LPC-DHA for 16 hours. (A) NSC<sup>WT</sup> cells showed increased DHA in PC, PE, and PS relative to NSC<sup>KO</sup> cells. …”
  2. 5802
  3. 5803
  4. 5804
  5. 5805

    S2 File - by Alejandro Valencia (16007329)

    Published 2023
    “…Using the RAMP Hybrid method, we estimate 264,516 [95% confidence interval [CI], 223,506–307,577] premature deaths attributable to PM<sub>2.5</sub> from all sources, a ~1% overall decrease in CMAQ-estimated premature mortality compared to RAMP Hybrid, despite increases and decreases in some locations. …”
  6. 5806

    Minimal dataset. by Lilishia Gounder (15240167)

    Published 2024
    “…We obtained 7,639,978 HIV VL records from 736 healthcare facilities across KZN, of which 1,031,171 (13.5%) had detectable VLs (i.e., VLs ≥400 copies/millilitre (mL)). …”
  7. 5807
  8. 5808

    Data_Sheet_1_Herpes Simplex Virus 1 UL2 Inhibits the TNF-α–Mediated NF-κB Activity by Interacting With p65/p50.pdf by Mingsheng Cai (286548)

    Published 2020
    “…<p>Herpes simplex virus 1 (HSV-1) is a large double-stranded DNA virus that encodes at least 80 viral proteins, many of which are involved in the virus–host interaction and are beneficial to the viral survival and reproduction. …”
  9. 5809
  10. 5810
  11. 5811
  12. 5812
  13. 5813

    A proposed model of the equilibrium between vesicular and surface-localized AQP5. by Philip Kitchen (827054)

    Published 2015
    “…<p>Panel A shows wild-type AQP5 under isotonic conditions. The large arrows represent an increase in AQP5 translocation (and the small arrows are a decrease). …”
  14. 5814
  15. 5815
  16. 5816
  17. 5817

    Identification of a Hydroxypyrimidinone Compound (<b>21</b>) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure by Wei Meng (505670)

    Published 2021
    “…Due to the increased polarity at C2, the permeability for these compounds decreased. Further adjustment of the polarity by replacing the N1 2,6-dimethoxyphenyl group with a 2,6-diethylphenyl group and reoptimization for the potency of the C5 pyrroloamides resulted in potent compounds with improved permeability. …”
  18. 5818

    Identification of a Hydroxypyrimidinone Compound (<b>21</b>) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure by Wei Meng (505670)

    Published 2021
    “…Due to the increased polarity at C2, the permeability for these compounds decreased. Further adjustment of the polarity by replacing the N1 2,6-dimethoxyphenyl group with a 2,6-diethylphenyl group and reoptimization for the potency of the C5 pyrroloamides resulted in potent compounds with improved permeability. …”
  19. 5819

    Identification of a Hydroxypyrimidinone Compound (<b>21</b>) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure by Wei Meng (505670)

    Published 2021
    “…Due to the increased polarity at C2, the permeability for these compounds decreased. Further adjustment of the polarity by replacing the N1 2,6-dimethoxyphenyl group with a 2,6-diethylphenyl group and reoptimization for the potency of the C5 pyrroloamides resulted in potent compounds with improved permeability. …”
  20. 5820